

[Amodiaquine - sulfadoxine + pyrimethamine](#)

Statut de médicament essentiel

Section:

[6. Anti-infective medicines 6.5. Antiprotozoal medicines 6.5.3. Antimalarial medicines 6.5.3.2. Antimalarial medicines > Medicines for chemoprevention](#)

Codes ATC: [P01BA06](#) [P01BD51](#)

EMLc

Indication

Malaria Code ICD11: [1F4Z](#)

INN

Amodiaquine + sulfadoxine + pyrimethamine

Type de médicament

Chemical agent

Type de liste

Liste de base

Formulations

Oral > Solid > dispersible tablet: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package (EMLc) ; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package (EMLc) ; 75 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] in co-package (EMLc) ; 150 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] in co-package (EMLc)

Historique des statuts LME

Ajouté pour la première fois en 2019 ([TRS 1021](#))

Modifié en 2025 ([TRS 1064](#))

Sexe

Tous

Âge

Enfants (1 mois - 12 ans)

Équivalence thérapeutique

La recommandation concerne ce médicament spécifique

Renseignements sur le brevet

Patents have expired in most jurisdictions

Lire la suite [sur les brevets](#).

Wikipédia

[Amodiaquine - sulfadoxine + pyrimethamine](#)

DrugBank

[Amodiaquine](#),

[Sulfadoxine](#),

[Pyrimethamine](#)

Résumé des preuves et recommandation du comité d'experts

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of new strengths of co-packaged amodiaquine with sulfadoxine + pyrimethamine to the EMLc for seasonal malaria chemoprevention in children.